drugset / Trial / NCT07228195
SGLT2i Therapy in Islet Transplantation (SIT)
RandomizedParallel-groupOpen-labelTreatment
Summary
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Timeline
- Start
- 2026-07-15
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Empagliflozin | Small molecule | 25 mg | Oral |